In the midst of swirling controversy about high insulin prices, Eli Lilly has announced that it’s reducing the cost of its most commonly prescribed — and older — insulins by 70 percent and expanding its program that caps patient out-of-pocket costs at $35 per month.
Source: Drug Industry Daily